With shares of Wal-Mart (NYSE:WMT) trading around $74, is WMT an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementWal-Mart operates retail stores in various formats around the world. The company aims to price items at the lowest price every day. Wal-Mart operates in three business segments: the Walmart U.S. segment, the Walmart International segment, and the Sam�� Club segment. It manages retail stores, restaurants, discount stores, supermarkets, super centers, hypermarkets, warehouse clubs, apparel stores, Sam��� Clubs, neighborhood markets, and other small formats, as well as Walmart.com and Samsclub.com. Through its retail channels, Wal-Mart is able to provide a variety of products and services at affordable prices to consumers and companies worldwide.
Wal-Mart may see increased competition as talks of the upcoming Alibaba IPO continue to heat-up. Alibaba has some big plans aside from the Chinese e-commerce giant�� upcoming IPO. Alibaba is planning to invest $16 billion between now and 2020 to build out its infrastructure, with the goal of reaching millions of consumers in China�� interior. Reuters reports that about $15 billion will come from the company�� IPO, which has been rumored to take place in the U.S. Alibaba Chief Executive Jonathan Lu told Reuters that he expects the company�� transactions to reach $490 billion by 2016, which will top Wal-Mart, making Alibaba the largest retailer in the world.
Top 10 Diversified Bank Stocks To Watch For 2015: Greif Inc (GEF)
Greif, Inc., incorporated on January 25, 1926, is a producer of industrial packaging products and services with manufacturing facilities located in over 50 countries. The Company offers a line of industrial packaging products, such as steel, fiber and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and reconditioned containers, and services such as container lifecycle management, blending, filling and other packaging services, logistics and warehousing. It also produces containerboard and corrugated products for niche markets in North America. It sells timber to third parties from its timberland in the south-eastern United States. It has four segments: Rigid Industrial Packaging & Services, Flexible Products & Services, Paper Packaging and Land Management.
Rigid Industrial Packaging and Services
In the Rigid Industrial Packaging and Services, the Company is a provider of rigid industrial packaging products, including steel, fiber and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and reconditioned containers, and services, such as container lifecycle management, blending, filling and other packaging services, logistics and warehousing. It sells industrial packaging products to customers in industries, such as chemicals, paints and pigments, food and beverage, petroleum, industrial coatings, agricultural, pharmaceutical and mineral, among others.
Flexible Products and Services segment
In the Flexible Products and Services segment, the Company is a producer of flexible intermediate bulk containers and a North American provider of industrial and consumer multiwall bag products. Its flexible intermediate bulk containers consist of a polypropylene-based woven fabric that is partly produced at its production sites, as well as sourced from strategic regional sup! pliers. Its industrial and consumer multiwall bag products are used to ship a range of industrial and consumer products, such as seed, fertilizers, chemicals, concrete, flour, sugar, feed, pet foods, popcorn, charcoal and salt, primarily for the agricultural, chemical, building products and food industries.
Paper Packaging segment
In the Paper Packaging segment, the Company sells containerboard, corrugated sheets and other corrugated products to customers in North America in industries such as packaging, automotive, food and building products. Its corrugated container products are used to ship such products as home appliances, small machinery, grocery products, building products, automotive components, books and furniture, as well as numerous other applications. Operations related to industrial and consumer multiwall bag products have been reclassified to Flexible Products and Services segment.
Land Management segment
In the Land Management segment, the Company is focused on the active harvesting and regeneration of the United States timber properties to achieve long-term yields. It also sells, from time to time, timberland and special use land, which consists of surplus land, HBU land and development land. As of October 31, 2013, it owned approximately 252,475 acres of timber property in the southeastern United States and approximately 10,300 acres of timber property in Canada.
Advisors' Opinion:- [By Geoff Gannon]
For those of you wondering if Greif Brothers Cooperage has any relation to Greif (GEF) ��yes. It has every relation. It�� the same exact company. And it�� still in pretty much the same business. They used to just make barrels. Now they make all kinds of different drums, containers, etc. That�� not a very big change for a company to make over 60 years or so.
Top 10 Supermarket Companies To Watch For 2014: United-Guardian Inc.(UG)
United-Guardian, Inc. researches, develops, manufactures, and markets cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products in the United States, Canada, China, France, and internationally. Its personal care products include LUBRAJEL, a line of water-based moisturizing and lubricating gel formulations; KLENSOFT, a surfactant for cosmetic formulations; UNITWIX, a cosmetic additive used as a thickener for oils and oil-based liquids; CONFETTI DERMAL DELIVERY FLAKES for use in various water-based products; ORCHID COMPLEX, a base for cosmetics; LUBRASLIDE and B-122 lubricants used in cosmetics; AQUATHIK, a powder used as a gelling agent for aqueous solutions or emulsions; and HYDRAJEL PL, a personal lubricant for the feminine personal care market. The company?s medical products comprise LUBRAJEL RR and RC water-based gels used as lubricants for catheters; LUBRAJEL MG to lubricate urinary catheters, prelubricated enema tips, and other medical devices; LUBRAJEL LC, a mouth moisturizer for oral use; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceuticals consists of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial for use in urology and surgery to treat infections in the urinary bladder. United-Guardian?s industrial products include DESELEX Liquid, a sequestering and chelating agent; and POLYCOMPLEX M and Q complexing agents to produce clear solutions of water-insoluble materials. The company distributes its products to drug wholesalers, drug stores, hospitals, physicians, long-term care facilities, Veteran?s Administration, and other government agencies through marketing partners, distributors, advertising in medical and trade journals, mailings to physicians, and exhibitions. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.
Advisors' Opinion:- [By Marc Bastow]
Cosmetics maker United-Guardian (UG) raised its semi-annual dividend 13% to 50 cents per share, payable on Dec. 20 to shareholders of record as of Dec. 6. This marks the 37th consecutive annual increase to the dividend.
UG Dividend Yield: 4.86%
Top 10 Supermarket Companies To Watch For 2014: Tower International Inc.(TOWR)
Tower International, Inc. operates as an integrated global manufacturer of engineered structural metal components and assemblies to automotive original equipment manufacturers. It offers body-structure stampings, frames, and other chassis structures, as well as complex welded assemblies for small and large cars, crossovers, pickups, and sport utility vehicles. The company?s products comprise body structures and assemblies that include structural metal components, such as body pillars, roof rails, and side sills; and Class A surfaces and assemblies that consist of body sides, hoods, doors, fenders, and pickup truck boxes. Tower International, Inc. also provides lower vehicle frames and structures, including pickup truck and SUV full frames, automotive engine and rear suspension cradles, floor pan components, and cross members; body-in-white assemblies, which comprise front and rear floor pan assemblies, and door/pillar assemblies; stamped, formed, and welded suspension com ponents, such as control arms, suspension links, track bars, spring and shock towers, shackles, twist axles, radius arms, stabilizer bars, trailing axles, and brackets; and other automotive products, and defense and aerospace products. It sells its products directly in North America, South America, Europe, and Asia. The company was formerly known as Tower Automotive, LLC and changed its name to Tower International, Inc. in October 2010. Tower International, Inc. was founded in 1993 and is headquartered in Livonia, Michigan.
Advisors' Opinion:- [By With assistance from Sofia Horta e Costa]
Tower International Inc. (TOWR), a maker of metal components for the automotive industry, fell 5.1 percent to $20.14 after saying an affiliate of Cerberus Capital Management LP plans to sell about 2.6 million shares in the company.
Top 10 Supermarket Companies To Watch For 2014: Dale Jarrett Racing Adventure Inc (DJRT)
Dale Jarrett Racing Adventure, Inc., incorporated on November 24, 1998, offers entertainment based oval driving schools and events. The Company owns several National Association for Stock Car Auto Racing (NASCAR) type racecars. These classes are conducted at various racetracks throughout the country. As of December 31, 2011, the Company owned 15 racecars, and had purchased six additional racecars for its Las Vegas hub. These racecars are classified as stock cars and are equipped for oval or round tracks only.
The Company offers five types of ride or drive programs for individuals and corporations. The Qualifier is a three lap ride with a professional driver, which lasts about five minutes, depending on the length of the track. The Season Opener is a half day training class culminating in the student driving 10 laps. The Rookie Adventure and Happy Hour are also half day driving classes with the students driving 20 or 30 laps, respectively. The Advanced Stock Car Adventure is a full day 60 lap class. The main purpose of each event is the thrill of actually driving the race car. It owns a Miller Semi Tractor Trailer to haul the cars from track to track. The Company also offers a range of add-on sale items, including compact disks (CDs) from its adventure cam located in the car, clothing, souvenirs and photography.
The Company competes with Richard Petty Driving Experience.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Alliance Creative Group Inc (OTCMKTS: ACGX), Dale Jarrett Racing Adventure Inc (OTCMKTS: DJRT), Inscor Inc (OTCMKTS: IOGA) and Solar Thin Films Inc (OTCMKTS: SLTZ) have all been getting some attention lately in various investment newsletters and it should come as no surprise that two out of four of these stocks have been the subject of paid promotions ��which tend to benefit traders. However, two out of four of these stocks also have pretty good financials for being small cap OTC stocks and that might make them attractive to investors with a long term time horizon. So which of these stocks might make traders some profits in the short term and investors some profits over the longer term? Here is a closer look to help you decide:
Top 10 Supermarket Companies To Watch For 2014: AstraZeneca PLC (AZN)
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.
Cardiovascular
The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.
Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.
The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.
Gastrointestinal
AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.
Infection
The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.
Neuroscience
AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).
Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.
Oncology
AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.
Advisors' Opinion:- [By Philip Springer]
This was a big week for the global pharmaceutical industry. First, rumors of one deal suggested a possible return to the industry’s old self-destructive ways. But then two other transactions were announced that signaled continuation of a newer trend that’s much healthier for shareholders.
On Monday, it was reported that New York-based Pfizer Inc. (NYSE: PFE) had been in talks to acquire AstraZeneca PLC (NYSE: AZN), headquartered in London, for over $100 billion. The companies apparently broke off the discussions.
If such a transaction were to occur, it would be the latest in a long series of megamergers that characterized the corporate strategies of Pfizer, Swiss drug giant Novartis AG (NYSE: NVS) and others in the 1990s and 2000s. Back then, the aim was to acquire rivals in multibillion-dollar deals that broadened the buyers’ businesses to cover more diseases and new health-care areas.
The catalyst for this buying binge was the so-called patent cliff, in which some of the sector’s biggest drugs faced the loss of patents that protected them from competition, resulting in reduced revenues and earnings.
Since then, however, the patent cliff problem has waned because many of those patent expirations have already occurred. And the bigger, combined companies generally have come up short on development of new blockbuster drugs. Also, excessive diversification has brought weak competitive positions in some niches.
But the current industry trend is for companies to focus more on their core strengths instead of diversifying. Pfizer, Bristol-Myers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) have made such moves over the last few years in order to focus on what they consider higher-growth prospects.
Tuesday brought more of the same. Novartis and UK-based GlaxoSmithKline (NYSE: GSK) announced more than $20 billion in deals. Novartis is to sell its animal-drugs busi - [By Maynard Paton]
LONDON -- The shares of�AstraZeneca� (LSE: AZN ) (NYSE: AZN ) added 6 pence to 3,359 pence during early London trade this morning after the company said it will write off $140 million following the outcome of a product trial.
- [By Brian Orelli]
Roche and AstraZeneca (NYSE: AZN ) also have drugs that target the PD-1 pathway, but they're further behind and not an immediate threat (at the moment).
Top 10 Supermarket Companies To Watch For 2014: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By Bio-Wire]
Another company that has benefitted from Inovio�� newfound attention is OncoSec Medical (OTC: ONCS) ��a newer ��ffshoot�� company that uses a similar but distinctly different electroporation device known as the OncoSec Medical System (OMS) that is based on Inovio�� technology. The specific amplitude and frequency of the OMS electroporation is calibrated such that plasmid delivery into solid tumor masses is fully optimized, while CELLECTRA electroporation is less specialized and focus more on the vaccination of skin cells. The cross-license agreement made between Inovio and Oncosec also covers the two devices for their distinctly different applications.
- [By James E. Brumley]
How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.
Top 10 Supermarket Companies To Watch For 2014: RCM Technologies Inc.(RCMT)
RCM Technologies, Inc., together with its subsidiaries, engages in the design, development, and delivery of business and technology solutions for commercial and government sectors in North America. It operates through three segments: Information Technology (IT), Engineering, and Commercial Services. The IT segment provides enterprise business solutions, application services, infrastructure solutions, competitive advantage and productivity solutions, and life sciences solutions. The Engineering segment offers engineering and design, engineering analysis, engineer-procure-construct, configuration management, hardware/software validation and verification, quality assurance, technical writing and publications, manufacturing process planning and improvement, reliability centered maintenance, component and equipment testing, and risk management engineering services. The Commercial Services segment provides long-term and short-term staffing, executive search, and placement servic es in various fields, including rehabilitation, nursing, managed care, allied health care, health care management, and medical office support, as well as offers in-patient, outpatient, sub-acute and acute care, multilingual speech pathology, rehabilitation, geriatric, pediatric, and adult day care services to hospitals, long-term care facilities, schools, sports medicine facilities, and private practices. This segment also offers contract and temporary services, and permanent placement services for full-time and part-time personnel in various functional areas, including office, clerical, data entry, secretarial, light industrial, shipping, receiving, and general warehousing. The company offers its services to aerospace/defense, energy, financial services, life sciences, manufacturing and distribution, public sector, and technology industries. RCM Technologies, Inc. was founded in 1971 and is based in Pennsauken, New Jersey.
Advisors' Opinion:- [By CRWE]
RCM Technologies, Inc. (Nasdaq:RCMT) reported that primarily due to unexpected and extended client procedural delays in awarding certain engagements under an existing contract with a major North American utility, the Company’s second quarter revenues and operating income will fall short of its expectations.
No comments:
Post a Comment